Pulmonx officer sells 14,245 shares at $2.26

Pulmonx’s chief science and technology officer sold 14,245 shares to cover tax withholding from RSU vesting at a reported price of $2.26.

Rhea-AI Filing Summary

Pulmonx Corp (LUNG) reported that Chief Science & Technology Officer Radhakrishnan Srikanth sold an aggregate of 14,245 shares of common stock on September 1, 2026 at $2.26 per share. The filing states each sale was made to cover tax withholding obligations arising from vesting of Restricted Stock Units granted between March 2023 and March 2026. No Rule 10b5-1 trading plan is indicated, and post-transaction share holdings are not reported in this filing.

Insider Trade Summary

Net Seller: 14,245 shares

Net Sell 4 txns

Insider Radhakrishnan Srikanth

Role Chief Science & Techn. Officer

Sold 14,245 shs ($32K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1	2,643	$2.26	$6K
Sale	Common Stock F2	2,121	$2.26	$5K
Sale	Common Stock F3	3,618	$2.26	$8K
Sale	Common Stock F4	5,863	$2.26	$13K

Holdings After Transaction: Common Stock — 316,994 shares (Direct)

Footnotes (4)

1. F1. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units (the "RSUs") granted on March 1, 2023.
2. F2. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs granted on March 1, 2024.
3. F3. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs granted on March 3, 2025.
4. F4. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs granted on March 2, 2026.

Key Figures

Total shares sold: 14,245 shares Sale price per share: $2.26 per share First transaction shares: 2,643 shares +4 more

7 metrics

Total shares sold 14,245 shares Aggregate common stock sales by Radhakrishnan Srikanth on September 1, 2026

Sale price per share $2.26 per share Reported price for each sale transaction on September 1, 2026

First transaction shares 2,643 shares Shares sold to cover tax withholding for RSUs granted March 1, 2023

Second transaction shares 2,121 shares Shares sold to cover tax withholding for RSUs granted March 1, 2024

Third transaction shares 3,618 shares Shares sold to cover tax withholding for RSUs granted March 3, 2025

Fourth transaction shares 5,863 shares Shares sold to cover tax withholding for RSUs granted March 2, 2026

Number of sale transactions 4 Total non-derivative sale transactions reported on September 1, 2026

Key Terms

Restricted Stock Units, tax withholding obligations, Rule 10b5-1

3 terms

Restricted Stock Units financial

"in connection with the vesting of the Restricted Stock Units (the "RSUs") granted"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding obligations financial

"sold by the reporting person to cover tax withholding obligations in connection"

Rule 10b5-1 regulatory

"The Rule 10b5-1 checkbox is not selected for these transactions"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

FAQ

What insider transaction did Pulmonx Corp (LUNG) disclose in this Form 4?

Pulmonx Corp disclosed that Chief Science & Technology Officer Radhakrishnan Srikanth sold 14,245 shares of common stock on September 1, 2026 at $2.26 per share, reported as open-market or private sales.

Why did the Pulmonx (LUNG) officer sell 14,245 shares?

The filing states the 14,245 shares were sold by Radhakrishnan Srikanth to cover tax withholding obligations associated with the vesting of Restricted Stock Units granted on March 1, 2023, March 1, 2024, March 3, 2025, and March 2, 2026.

At what price were the Pulmonx (LUNG) insider shares sold?

All reported sales by Radhakrishnan Srikanth on September 1, 2026 were executed at a reported price of $2.26 per share of Pulmonx common stock.

Were the Pulmonx (LUNG) insider sales made under a Rule 10b5-1 plan?

No. The Form 4 indicates the Rule 10b5-1 checkbox is not selected, and the footnotes do not state that the September 1, 2026 sales were made under any Rule 10b5-1 trading plan.

How many separate transactions did the Pulmonx (LUNG) officer report?

Radhakrishnan Srikanth reported four separate sale transactions of Pulmonx common stock on September 1, 2026, totaling 14,245 shares, each linked to tax withholding for different RSU grant vestings.

Does the Form 4 show Radhakrishnan Srikanth’s remaining Pulmonx (LUNG) holdings?

No. For each of the four September 1, 2026 sale transactions, the field for total shares following the transaction is left blank, so remaining holdings are not disclosed in this filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/03/2026 - 06:26 PM Accepted by SEC EDGAR 09/03/2026 - 06:21 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Radhakrishnan Srikanth

(Last) (First) (Middle)

C/O PULMONX CORPORATION

700 CHESAPEAKE DRIVE

(Street)

REDWOOD CITY CALIFORNIA 94063

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Pulmonx Corp [ LUNG ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Science & Techn. Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/01/2026		S(1)		2,643	D	$2.26	328,596	D
Common Stock	09/01/2026		S(2)		2,121	D	$2.26	326,475	D
Common Stock	09/01/2026		S(3)		3,618	D	$2.26	322,857	D
Common Stock	09/01/2026		S(4)		5,863	D	$2.26	316,994	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units (the "RSUs") granted on March 1, 2023.

2. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs granted on March 1, 2024.

3. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs granted on March 3, 2025.

4. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs granted on March 2, 2026.

	/s/ David Aaron Lehman, Attorney-in-Fact	09/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)